We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Peptide Binding Enhances Removal of Iron from the Blood

By Biotechdaily staff writers
Posted on 12 Nov 2007
Researchers have found that use of a novel seven amino acid peptide in conjugation with the chelating agent Desferal significantly increased removal of iron from the serum protein ferritin.

Ferritin consists of 24 protein subunits. More...
In vertebrates these are both the light (L) and the heavy (H) type with a molecular weight of 19 kDA or 21 kDA, respectively. Inside the ferritin shell, iron ions form crystallites together with phosphate and hydroxide ions. The resulting particle is similar to the mineral ferrihydrite. Each ferritin complex can store about 4500 iron ions in its inner core or "cage”.

Desferal, otherwise known as deferoxamine or desferrioxamine, is a chelating agent used to remove excess iron from the body. It acts by binding free iron in the bloodstream and enhancing its elimination in the urine. By removing excess iron, the agent reduces the damage done to various organs and tissues, such as the liver. Desferal is used to treat acute iron poisoning, especially in small children. Treatment with this agent is also frequently necessary in patients with certain types of chronic anemia (e.g. thalassemia and myelodysplastic syndrome) who require many blood transfusions, which can greatly increase the amount of iron in the body.

Investigators at Children's Hospital Oakland Research Institute (CA, USA) scanned a library of small peptides for their ability to bind to ferritin. They reported in the November 2, 2007, edition of the Journal of Biological Chemistry that a peptide selected for ferritin pore binding increased the rate of iron demineralization 3-fold. Conjugating the peptide to Desferal increased the rates to 8-fold. These findings suggested that it might be possible to develop new medications that will improve the removal of excess iron in the blood of patients with certain blood diseases.

"We wanted to prove a hypothesis that a small protein or peptide could bind to ferritin and could be used to regulate ferritin pores,” said senior author Dr. Elizabeth Theil, a senior investigator at Children's Hospital Oakland Research Institute. "Our hypothesis was correct. We proved that when a binding peptide of seven amino acids, a heptapeptide, is coupled with Desferal the rate of removal of iron from ferritin is eight times faster.”


Related Links:
Children's Hospital Oakland Research Institute

Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The blood-based assay captures circulating chromatin, cell-free DNA fragments that are largely inaccessible through standard laboratory methods (image credit: Shuttertstock)

Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response

Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more

Immunology

view channel
Image: New research shows that autoimmunity drives debilitating long COVID symptoms in a subset of patients (Image credit: Shutterstock)

Study Points to Autoimmune Pathway Behind Long COVID Symptoms

Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.